Italia - italia - myHealthbox

guna - centella asiatica, pinus sylvestris - crema - aqua, methylpolysiloxane, ceramide 3, ceramide 611, ceramide 1, phytosphingosine, cholesteroi, sodium lauroyl lactylate, xanthan gum, cetearyl alcohol, glycerin, ppg-11 stearyl ether, steareth-2, centella asiatica, stearic acid, pinus sylvestris - dermocosmetici - trattamento estetico di segni e cicatrici

Italia - italia - AIFA (Agenzia Italiana del Farmaco)

industria farmaceutica nova argentia s.r.l. - sulfadiazina - sulfadiazina

Italia - italia - AIFA (Agenzia Italiana del Farmaco)

s.a.l.f. spa laboratorio farmacologico - sulfadiazina - sulfadiazina

Italia - italia - AIFA (Agenzia Italiana del Farmaco)

farmaceutici gellini spa - sulfadiazina - sulfadiazina

Italia - italia - AIFA (Agenzia Italiana del Farmaco)

bioprogress s.p.a. - sulfadiazina - sulfadiazina

Italia - italia - AIFA (Agenzia Italiana del Farmaco)

officina farmaceutica fiorentina s.r.l. - sulfadiazina - sulfadiazina

Italia - italia - AIFA (Agenzia Italiana del Farmaco)

c.o.c. farmaceutici s.r.l. - sulfadiazina - sulfadiazina

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

weleda ag - echinacea angustifolia e planta tota rh tm (ph.eur.hom. 1.5.1), euphrasia stricta et euphrasia officinalis e planta tota rh tm (ph.eur.hom. 1.5.1), calendula officinalis e floribus cum calycibus paraffinum liquidum tm (hab 57) - il collirio - echinacea angustifolia e planta tota rh tm (ph.eur.hom. 1.5.1) 30 mg, euphrasia stricta et euphrasia officinalis e planta tota rh tm (ph.eur.hom. 1.5.1) 50 mg, calendula officinalis e floribus cum calycibus paraffinum liquidum tm (hab 57) 50 mg, vaselinum album, paraffinum liquidum, aqua ad iniectabile, cholesterolum, ad unguentum pro 1 g. - zulassung mit reduziertem dossier ohne indikation nach art. 25 abs. 1 kpav (sr 812.212.24) - antroposofici

Euroopan unioni - italia - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - fibrosi cistica - altri prodotti per il sistema respiratorio - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 e 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 e 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Euroopan unioni - italia - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - sleep initiation and maintenance disorders - psicolettici - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.